USPSTF2013与PLCOm2012肺癌筛查入选标准比较(国际肺癌筛查试验):前瞻性队列研究的中期分析
国际肺癌筛查试验前瞻性比较USPSTF2013标准与PLCOm2012模型(6年风险≥1.70%)筛选肺癌筛查人群的效果。在平均随访2.3年的4540名参与者中,PLCOm2012组检出162例肺癌,USPSTF2013组检出135例,癌症灵敏度差异15.8%。PLCOm2012组年龄更大、合并症更多、预期寿命更短,但肺癌患者累积预期寿命更高。
要点
- PLCOm2012模型(6年风险≥1.70%)较USPSTF2013标准检出更多肺癌,灵敏度差异15.8%。
- PLCOm2012组参与者年龄更大、合并症更多、预期寿命更短。
- PLCOm2012组肺癌患者累积预期寿命高于USPSTF2013组,差异247.9年。
核心结论
- PLCOm2012模型在筛选肺癌筛查项目入选者方面似乎比USPSTF2013标准更高效,应用于识别可从筛查项目中获益的高危个体。
研究设计与样本
- 前瞻性队列研究,纳入国际肺癌筛查试验(ILST)中55-80岁、现在或既往吸烟(吸烟史≥30包年或戒烟≤15年)、符合USPSTF2013标准或PLCOm2012 6年风险≥1.51%的参与者,来自加拿大、澳大利亚、香港和英国的九个筛查点。
- 入组后按USPSTF2013标准和PLCOm2012模型6年风险阈值≥1.70%进行评估,主要结局为两种标准间肺癌检出率和肺癌患者累积预期寿命的比较,本文为中期分析。
- 为估算USPSTF2013阴性且PLCOm2012 6年风险<1.51%个体的肺癌发病率,将符合这些标准的PLCO试验吸烟者肺癌发病率应用于ILST样本量及平均随访时间。
主要发现
- 2015年6月17日至2020年12月29日共纳入5819名参与者,USPSTF2013标准和PLCOm2012模型(6年风险≥1.51%)各选出4540名(78%)个体。
- 平均随访2.3年(SD 1.0),USPSTF2013阳性组4540人中发生135例肺癌,PLCOm2012 6年风险≥1.70%组4540人中发生162例,癌症灵敏度差异15.8%(95% CI 10.7-22.1%),绝对比值比4.00(95% CI 1.89-9.44),p<0.0001。
- 与USPSTF2013阳性个体相比,PLCOm2012入选者年龄更大(平均65.7岁[SD 5.9] vs 63.3岁[5.7],p<0.0001),合并症更多(中位数2[IQR 1-3] vs 1[1-2],p<0.0001),预期寿命更短(13.9年[95% CI 12.8-14.9] vs 14.8年[13.6-16.0])。
- 肺癌患者累积预期寿命的模型估计差异在PLCOm2012 6年风险≥1.70%组高于USPSTF2013阳性组(2248.6年[95% CI 2089.6-2425.9] vs 2000.7年[1841.2-2160.3];差异247.9年,p=0.015)。
临床怎么用
- 作者认为PLCOm2012模型在筛选肺癌筛查项目入选者方面似乎比USPSTF2013标准更高效,应用于识别可从筛查项目中获益的高危个体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer is a major health problem. CT lung screening can reduce lung cancer mortality through early diagnosis by at least 20%. Screening high-risk individuals is most effective. Retrospective analyses suggest that identifying individuals for screening by accurate prediction models is more efficient than using categorical age-smoking criteria, such as the US Preventive Services Task Force (USPSTF) criteria. This study prospectively compared the effectiveness of the USPSTF2013 and PLCOm2012 model eligibility criteria. METHODS: In this prospective cohort study, participants from the International Lung Screening Trial (ILST), aged 55-80 years, who were current or former smokers (ie, had ≥30 pack-years smoking history or ≤15 quit-years since last permanently quitting), and who met USPSTF2013 criteria or a PLCOm2012 risk threshold of at least 1·51% within 6 years of screening, were recruited from nine screening sites in Canada, Australia, Hong Kong, and the UK. After enrolment, patients were assessed with the USPSTF2013 criteria and the PLCOm2012 risk model with a threshold of at least 1·70% at 6 years. Data were collected locally and centralised. Main outcomes were the comparison of lung cancer detection rates and cumulative life expectancies in patients with lung cancer between USPSTF2013 criteria and the PLCOm2012 model. In this Article, we present data from an interim analysis. To estimate the incidence of lung cancers in individuals who were USPSTF2013-negative and had PLCOm2012 of less than 1·51% at 6 years, ever-smokers in the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) who met these criteria and their lung cancer incidence were applied to the ILST sample size for the mean follow-up occurring in the ILST. This trial is registered at ClinicalTrials.gov, NCT02871856. Study enrolment is almost complete. FINDINGS: Between June 17, 2015, and Dec 29, 2020, 5819 participants from the International Lung Screening Trial (ILST) were enrolled on the basis of meeting USPSTF2013 criteria or the PLCOm2012 risk threshold of at least 1·51% at 6 years. The same number of individuals was selected for the PLCOm2012 model as for the USPSTF2013 criteria (4540 [78%] of 5819). After a mean follow-up of 2·3 years (SD 1·0), 135 lung cancers occurred in 4540 USPSTF2013-positive participants and 162 in 4540 participants included in the PLCOm2012 of at least 1·70% at 6 years group (cancer sensitivity difference 15·8%, 95% CI 10·7-22·1%; absolute odds ratio 4·00, 95% CI 1·89-9·44; p<0·0001). Compared to USPSTF2013-positive individuals, PLCOm2012-selected participants were older (mean age 65·7 years [SD 5·9] vs 63·3 years [5·7]; p<0·0001), had more comorbidities (median 2 [IQR 1-3] vs 1 [1-2]; p<0·0001), and shorter life expectancy (13·9 years [95% CI 12·8-14·9] vs 14·8 [13·6-16·0] years). Model-based difference in cumulative life expectancies for those diagnosed with lung cancer were higher in those who had PLCOm2012 risk of at least 1·70% at 6 years than individuals who were USPSTF2013-positive (2248·6 years [95% CI 2089·6-2425·9] vs 2000·7 years [1841·2-2160·3]; difference 247·9 years, p=0·015). INTERPRETATION: PLCOm2012 appears to be more efficient than the USPSTF2013 criteria for selecting individuals to enrol into lung cancer screening programmes and should be used for identifying high-risk individuals who benefit from the inclusion in these programmes. FUNDING: Terry Fox Research Institute, The UBC-VGH Hospital Foundation and the BC Cancer Foundation, the Alberta Cancer Foundation, the Australian National Health and Medical Research Council, Cancer Research UK and a consortium of funders, and the Roy Castle Lung Cancer Foundation for the UK Lung Screen Uptake Trial.
引用
- Tammemägi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021. PMID: 34902336. doi:10.1016/S1470-2045(21)00590-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。